ALS Stem Cell Therapy: Too Soon to Tell
NSI-566/ALS Principal Investigator, Dr. Eva Feldman’s, presentation of Phase I data at the American Neurological Association annual meeting, is reported in this article which cites the three of 15 Phase I patients “receiving the most extensive injections showed stabilization of functional scores after almost 2 years of follow-up.”
P2P MDA Night of Hope
NSI-566/ALS Phase I patient #12, Edward Tessaro’s, story with ALS is spotlighted on the eve of the 8th Annual MDA-ALS Night of Hope benefit in Atlanta. Site Principal Investigator, Emory’s Dr. Jonathan D. Glass, is also interviewed in this segment which includes surgery footage of the cell therapy treatment using Neuralstem’s proprietary breakthrough medical devices, the Spinal Platform and Floating Cannula.
ALS stem cell trial begins at U-M Health System with first two patients receiving injections
The first two NSI-566/ALS patients to be treated at the University of Michigan Health System and the Phase II trial are the focus of this article that also introduces Parag Patil, MD, PhD, the U-M neurosurgeon and biomedical engineer, who performed the surgeries. Dr. Patil is an engineering consultant to Neuralstem to further develop its proprietary cell therapy-delivery device.
Phase II of ALS stem cell trial underway at Emory and University of Michigan
Emory’s NSI-566/ALS Site Principal Investigator, Jonathan D. Glass, MD, and Co-Investigator and Neurosurgeon Nicholas M. Boulis, MD, who designed Neuralstem’s proprietary, patented spinal platform and floating cannula specifically for the world’s first delivery of cells directly into the gray matter of the spinal cord, are interviewed about the Phase II trial now underway.
ALS patient walking, showing improvement after stem cell treatment
FOX News Detroit’s Deena Centofanti speaks with NSI-566/ALS Principal Investigator Eva Feldman, MD, PhD, and Phase I patient, Ted Harada, in a “Health Works” feature on Neuralstem’s “landmark study” with collaborators at the University of Michigan and Emory University, on the eve of the Phase II trial.